Champions Oncology (CSBR) Receivables (2011 - 2026)

Champions Oncology has reported Receivables for 16 years, with the latest figure at $21.8 million in Q2 2026.

• On a quarterly basis, Receivables rose 23.44% year-over-year to $21.8 million in Q2 2026; TTM through Apr 2026 was $21.8 million, a 23.44% increase from a year earlier, with the FY2026 full-year figure at $21.8 million, up 23.44% from the prior year.
• Receivables was $21.8 million for Q2 2026 at Champions Oncology, up from $19.2 million in the prior quarter.
• The five-year high for Receivables was $22.6 million in Q1 2025, with the low at $11.7 million in Q4 2023.
• Average Receivables over 5 years is $15.9 million, with a median of $15.0 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Receivables jumped 68.12% in 2025, then declined 14.83% in 2026.
• Over 5 years, Receivables stood at $13.3 million in 2022, then retreated by 12.12% to $11.7 million in 2023, then jumped by 54.89% to $18.1 million in 2024, then grew by 8.82% to $19.7 million in 2025, then grew by 10.34% to $21.8 million in 2026.
• The last three Receivables figures came in at $21.8 million (Q2 2026), $19.2 million (Q1 2026), and $19.7 million (Q4 2025), per Business Quant data.